Diagnostics
Artificial intelligence and machine learning could change the face of cancer diagnostics. BioSpace spoke with the University of Waterloo, Gina Life and OncoHost to find out how.
The worldwide market for therapeutics designed specifically for conditions and diseases that affect mainly women is expected to exceed $65 billion by 2027. BioSpace looks at three femtech leaders.
BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) (“BioMark” or the “Company”) (an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to reports that it will amend the term of the non-broker warrants (the “Warrants”) issued in relation to a private placement financing that closed on December 13, 2019 on a continuing effort to improve corporate value for its shareholders.
FUJIFILM Dyosynth Biotechnologies, Taysha Gene Therapies, Veravas highlight innovation stemming from the Lone Star state. BioSpace takes a deep dive into these and other Texas innovators.
The result will be two independent, publicly traded companies: Labcorp and The Clinical Development Business offering Phase I-IV clinical trial management and technology to the biopharma industry.
A silicon wafer offers the powerful insights of the human genome for the low price of $100. Ultima Genomics CEO Gilad Almogy discussed the therapeutic possibilities with BioSpace.
Researchers at Imperial College London have developed a novel diagnosis method with a high rate of correct Alzheimer’s diagnosis and the ability to determine the patient’s progression stage.
A blood test to diagnose Alzheimer’s disease launched in April by Quest Diagnostics has the potential to screen patients for risk years before symptoms appear.
Virongy is expanding again and has committed to a $471,000 expansion with up to 70 new jobs.
Recent funding saw support for a platform that selectively degrades DNA, software to help read mammograms and a company using corn genetics to develop cancer-targeting viruses.
PRESS RELEASES